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Research
Persistent organic pollutants (POPs) are under 
scrutiny because their sustainable storage in the 
adipose tissue might lead to a chronic internal 
exposure, possibly disrupting metabolic and 
endocrine functions. Recently, human studies 
have provided indirect evidence for the pos-
sible implication of these environmental pol-
lutants in metabolic disorders. Few studies have 
reported correlations between the plasma con-
centrations of certain POPs and metabolic traits 
(Ha et al. 2007, 2009; Lee et al. 2008; Uemura 
et al. 2009). These epidemiologic studies are in 
line with in vitro and animal data suggesting 
that POPs such as dioxin could impair insu-
lin secretion and action (Liu and Matsumura 
2006; Marchand et al. 2005; Piaggi et al. 2007) 
and interfere with adipogenesis (Liu et al. 1998; 
Shimba et al. 2001) and adipose tissue function 
(Brewster and Matsumura 1988; Lakshman 
et al. 1988). However, POPs comprise a large 
variety of pollutant families. Although these 
chemical families share physicochemical proper-
ties, their biological effects are diverse. Whereas 
polychlorinated dibenzo-p-dioxin (PCDDs), 
polychlorinated dibenzofurans (PCDFs), 
and “dioxin-like” polychlorinated biphenyls 
(dl-PCBs) act primarily through the activa-
tion of the aryl hydrocarbon receptor (AhR), 
other PCBs, brominated flame retardants, 
and organochlorine pesticides exhibit differ-
ent modes of action. Within a single family of 
pollutants such as dioxins, congeners exhibit 
different potencies, and little is known about 
their kinetic behavior in the organism, their 
distribution, or their bioavailability (Van den 
Berg et al. 2006).
Characterizing dynamic conditions lead-
ing to the release and redistribution of these 
pollutants can provide insights into the profile 
and kinetics of POPs and their putative patho-
genic effects in humans. Tremblay’s group in 
Canada studied the variations of plasma con-
centrations of selected POPs such as PCBs and 
organo  chlorine pesticides after diet-induced 
weight loss (Chevrier et al. 2000; Imbeault et al. 
2002). Moderate weight loss was associated 
with increased plasma concentrations of these 
POPs, suggesting a release of pollutants from fat 
mass that could be related to increased lipolysis. 
These effects were also observed during weight 
loss induced by bariatric surgery (Charlier et al. 
2002; Hue et al. 2006). These initial studies 
suggest that surgical or diet-induced weight loss 
represents a valuable model to study the effects 
of body POP redistribution on clinical and bio-
logical parameters in humans.
Critical questions remained unanswered. 
First, because body fat constitutes the reser-
voir of POPs, it is important to assess their 
adipose tissue concentrations, as well as 
their total body burden, in addition to their 
plasma levels in order to evaluate their kinetic 
behavior. Furthermore, although visceral and 
subcutaneous fat territories display different 
metabolic properties, it is unclear whether 
they behave similarly in terms of POP stor-
age. Second, a detailed characterization of 
all congeners within a family of pollutants is 
required to determine whether one of them 
could be representative of the others. Third, 
in addition to POP kinetics, it is important 
to assess their biological effects, for example, 
by studying their target gene expression, and 
to evaluate relationships between changes in 
POP abundance and various bioclinical varia-
tions occurring after body fat loss.
For this purpose, we measured a wide range 
of dioxins, furans, and PCB congeners in dif-
ferent fat depots and plasma samples collected 
from lean and obese individuals and assessed 
total body burden before and after weight loss. 
We followed obese patients undergoing weight 
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Ba c k g r o u n d: In humans, persistent organic pollutants (POPs) are stored primarily in adipose 
  tissue. Their total body burden and their contribution to obesity-associated diseases remain unclear.
oBjectives: We characterized POP total body burden and their redistribution in obese individuals 
before and after drastic weight loss and compared these values with a variety of molecular, biologi-
cal, and clinical parameters.
Me t h o d s : Seventy-one obese subjects were enrolled and underwent bariatric surgery. Blood and 
adipose tissue samples were obtained at different times from these individuals as well as from 
18 lean women.
re s u l t s: POP content (17 dioxins/furans and 18 polychlorinated biphenyl congeners) in different 
adipose tissue territories was similar, allowing us to assess total POP body burden from a single 
biopsy. Total POP body burden was 2 to 3 times higher in obese than in lean individuals. We also 
found increased expression of some POP target genes in obese adipose tissue. Drastic weight loss led 
to increased serum POPs and, within 6–12 months, to a significant 15% decrease in total polychlo-
rinated biphenyl body burden. Importantly, serum POP levels were positively correlated with liver 
toxicity markers and lipid parameters, independently of age and body mass index.
co n c l u s i o n s: POP content in adipose tissue and serum correlate with biological markers of obesity- 
related dysfunctions. Drastic weight loss leads to a redistribution of POPs and to a moderate 
decrease of their total body burden.
key w o r d s : adipose tissue, bariatric surgery, dioxin, obesity, PCB, persistent organic pollutants, 
xenobiotic metabolizing enzymes. Environ Health Perspect 119:377–383 (2011).  doi:10.1289/
ehp.1002848 [Online 15 December 2010]Kim et al.
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loss through bariatric surgery and compared 
the POP profile, gene expression in adipose 
tissue depots and in blood, and a variety of 
biological and clinical parameters.
Materials and Methods
Subjects. A total of 71 obese subjects involved 
in a gastric surgery program were recruited 
between 2006 and 2008 in the Department 
of Nutrition, Center of Reference for 
Medical and Surgical Care of Obesity, Pitié-
Salpêtrière Hospital (Paris, France). The eth-
ics committee of the Hôtel-Dieu Hospital 
approved the clinical investigations both for 
obese and nonobese individuals. All sub-
jects gave a written informed consent after 
individual explanation. Patients met the cri-
teria for obesity surgery [body mass index 
(BMI) ≥ 40 kg/m2, or ≥ 35 kg/m2 with at 
least one comorbidity (hypertension, type 2 
diabetes, dyslipidemia, or obstructive sleep 
apnea syndrome); for the scheme of the study 
design, see Supplemental Material, Figure 1 
(doi:10.1289/ehp.1002848)].
Clinical and biological parameters. 
Adiposity-related markers were determined. 
BMI (kilograms per square meter) was cal-
culated from the measured body weight with 
the same scale and height. Fat and fat-free 
mass were determined by dual-energy X-ray 
absorptiometry (DXA; GE Lunar Prodigy 
Corp., Madison, WI, USA) (Table 1). Resting 
energy expenditure was measured in the obese 
subjects by indirect calorimetry after 12 hr of 
fasting (Quark Resting Metabolic Rate; Delta 
Medical, Soucieu-en-Jarrest, France). These 
evaluations were performed before and during 
the postsurgery follow-up. Periumbilical sur-
gical needle biopsies of subcutaneous adipose 
tissue were obtained before Roux-en-Y gastric 
bypass (RYGB) and during the follow-up, and 
omental adipose tissue was also collected at 
the time of surgery, as previously described 
(Mutch et al. 2009). After adipocyte isolation 
and collagenase digestion, adipocyte diameter 
was measured as described elsewhere (Prat-
Larquemin et al. 2004).
Blood samples were obtained at each time 
point in all subjects after 12 hr of fasting and 
stored at –20°C for later analysis. Biological 
parameters included lipid [total cholesterol, 
high-density lipoprotein (HDL) cholesterol, 
and triglycerides], insulin and glucose val-
ues, leptin, adiponectin, and inflammatory 
markers [e.g., highly sensitive C-reactive 
protein (hsCRP), interleukin (IL)-6, oroso-
mucoid]. Liver markers [aspartate transami-
nase (AST), alanine transaminase (ALT), and 
γ-glutamyltransferase (γGT)] were meas-
ured by routine tests. Homeostatic model 
assessment (HOMA) for insulin sensitivity 
(HOMA-S) and beta-cell function (HOMA-B) 
were estimated using the method described by 
Matthews et al. (1985). Metabolic syndrome 
traits in obese and lean subjects were clinically 
assessed based on consensual criteria proposed 
by Alberti et al. (2009).
PCDD/PCDF and PCB analysis. All 
organic solvents (Promochem, Molsheim, 
France) were picograde quality. Silica (Fluka, 
Buchs, Switzerland), sodium sulfate and dipo-
tassium oxalate (Merck, Darmstad, Germany), 
and acetic acid and sodium dodecyl sulfate 
were of superior analytical quality. Native and 
13C-labeled standards were purchased from 
Cambridge Isotope Laboratories (Andover, MA, 
USA) and Wellington Laboratory (Guelph, 
ON, Canada). Standard solutions were pre-
pared in toluene or isooctane for (PCDD/
PCDFs) and PCBs, respectively. All reference 
solutions were stored in darkness at < 6°C.
Before extraction, 17 13C-labeled PCDD/
PCDFs and 18 13C-labeled PCBs conge-
ners were added to each sample for internal 
standard calibration and quantification by 
the isotope dilution method. Sample prepara-
tion is described in detail in Supplemental 
Material (doi:10.1289/ehp.1002848).
PCDD/PCDF and PCB measurements 
were performed by gas chromatography cou-
pled to high-resolution mass spectrometry 
using an HP-5890 gas chromatograph (Hewlett 
Packard, Palo Alto, CA, USA) coupled to a 
JMS 700D or a JMS 800D double electromag-
netic sector high resolution mass spectrometer 
(Jeol, Tokyo, Japan). Analytical methods are 
described in detail in Supplemental Material 
(doi:10.1289/ehp.1002848).
Total POP burden is calculated by taking 
into account the concentration of POPs per 
gram of lipid in the adipose tissue and the 
total amount of fat in the body as calculated 
by DXA. Because, under the conditions of 
the study, POPs are primarily associated with 
fat, this value is a good estimate of total body 
burden.
Determination of target gene expression. 
Total RNA was extracted from adipose tissue 
with the RNeasy total RNA Mini kit (Qiagen, 
Courtaboeuf, France). Total RNA concentra-
tion was assessed spectrophotometrically with 
a NanoDrop (Labtec, Palaiseau, France) and 
their quality was determined with the Agilent 
2100 Bioanalyzer (Agilent Technologies, 
Massy, France). Total RNA (1 µg) was reverse 
transcribed using a high-capacity cDNA 
reverse transcription kit (Applied Biosystems, 
Courtaboeuf, France). Real-time polymerase 
chain reactions (PCRs) were conducted with 
absolute QPCR SYBR Green Rox mix (Thermo 
Electron SAS, Villebon sur Yvette, France) 
on ABI Prism 7900 (Applied Biosystems, 
Courtaboeuf, France). mRNA values were nor-
malized to the expression level of a reference 
gene by using the DDCT method (comparative 
Ct method) described in Supplemental Material 
(doi:10.1289/ehp.1002848). Primer sequences 
are available upon request.
Statistical analysis. Quantitative variables, 
including clinical and biological parameters 
as well as various POP contamination levels, 
measured in serum and adipose tissue samples 
are expressed as mean ± SE. We used Wilcoxon 
rank sum tests to assess statistical significance of 
differences in clinical and biological parameters 
and in POP contamination levels, between lean 
and obese subjects at baseline. Paired Wilcoxon 
rank sum tests were performed to analyze 
changes in these parameters between various 
time points after surgery. Multivariate analysis 
of variance was used to explore global varia-
tions of the analyzed parameters throughout 
the follow-up after surgery.
We used principal component analysis 
(PCA) combined with co-inertia analysis to 
explore complex and potentially redundant 
relationships involving a relatively large num-
ber of clinical and biological parameters, as 
Table 1. Characteristics of obese subjects before surgery and a group of normal-weight subjects.
Clinical and biological parameters Obese subjects (n = 71) Lean subjects (n = 18) p-Valuea
Age (years) 44 ± 1.6 39.18 ± 2.85 NS
Adiposity markers
BMI (kg/m2) 48 ± 0.79 21.67 ± 0.36 < 0.0001
Body weight (kg) 130.58 ± 2.98 59.1 ± 1.56 < 0.0001
Fat mass (kg) 58.21 ± 1.46 15.7 ± 9.7b < 0.0001
Fat-free mass (kg) 62.84 ± 1.46 40.6 ± 11b < 0.0001
Leptin (ng/mL) 54.95 ± 3.27 8.83 ± 1.11 < 0.001
Plasma glucose homeostasis
Glycemia (mmol/L) 6.07 ± 0.26 4.38 ± 0.12 < 0.01
Insulinemia (μU/mL) 18.27 ± 1.43 3.83 ± 0.38 < 0.0001
Adiponectin (μg/mL) 8.26 ± 0.93 13.39 ± 1.14 < 0.01
Plasma lipid homeostasis
Total cholesterol (mmol/L) 4.76 ± 0.12 5.02 ± 0.27 NS
Total triglycerides (mmol/L) 1.36 ± 0.08 0.89 ± 0.08 < 0.0001
HDL cholesterol (mmol/L) 1.26 ± 0.04 1.69 ± 0.09 < 0.0001
Inflammatory markers
Plasma hsCRP (mg/L) 10.48 ± 1.12 3.43 ± 1.02 < 0.0001
Plasma IL6 (pg/mL) 9.12 ± 2.26 3.35 ± 1.68 < 0.0001
NS, not significant.
aWilcoxon rank sum tests were used to compare obese and lean subjects. bData available in 12 subjects who agreed to 
the DXA measure.POPs in obese individuals during weight loss
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well as POP contamination levels, at baseline 
and after RYGB. Co-inertia analysis is a cou-
pling method for comparing different types 
of parameters presenting different variances. 
To estimate correlation between POPs and 
bioclinical variable, we used partial Spearman 
correlation coefficients (pRs) estimated by 
considering potentially confounding factors, 
such as age and sex, in a variance-covariance 
matrix computation.
The significance of the strongest dynamic 
associations, among those identified by PCA 
and co-inertia analysis, involving clinical- 
biological parameters and POP contamination 
levels, was further evaluated by building linear 
mixed-effects (LME) models to test for inter-
variable redundancies and to adjust for poten-
tial confounding factors. Age and sex were 
systematically considered as confounding cova-
riates in LME models. All LME models were 
fit by maximizing the restricted log-likelihood   
of their estimated coefficients. Statistical 
analyses were performed using the R soft-
ware (R Project for Statistical Computing, 
Vienna, Austria; http://www.r-project.org). 
PCA and co-inertia analyses were performed 
with “ade4” R package. LME modeling was 
performed by relying on statistical functions 
available in the “nlme” R package. All statisti-
cal computations with p-values < 0.05 were 
considered significant. 
Results
Clinical and biological characteristics before 
and after weight loss. Table 1 presents clini-
cal characteristics of lean and obese subjects.
As expected, obese subjects had higher leptin, 
fasting glucose, insulin, triglyceride serum, 
and inflammatory marker concentrations and 
lower adiponectin and HDL cholesterol serum 
concentrations compared with the lean ones.
Table 2 presents the profile of clinical and 
biological parameters related to body com-
position, metabolic, inflammatory, and liver 
markers in obese subjects. The amount of fat 
mass, adipocyte cell diameter, and serum lep-
tin concentrations decreased significantly, as 
expected. Bioclinical modifications were in 
agreement with an improvement of biological, 
metabolic, liver, and inflammatory parameters 
after RYGB.
POP levels in blood and different adipose 
depots. We examined the distribution of each 
pollutant congener, both in blood of lean ver-
sus obese subjects and in two adipose tissue 
depots in obese subjects. We next calculated 
the POP contamination level for each class 
of pollutants. The POP contamination levels 
were statistically similar in serum from obese 
versus lean patients, either on a lipid weight 
basis (picograms or nanograms per lipid 
weight) or on a fresh weight basis (picograms 
or nanograms per milliliter) (Figure 1A,B). 
Results obtained for adipose tissue are pre-
sented in Figure 1C, showing a significantly 
higher concentration (classically expressed 
relative to the extracted fat content, i.e., on a 
lipid weight basis) of PCDD/Fs in lean sub-
jects compared with obese subjects, whereas 
this tendency was not statistically significant 
for dl-PCBs and was borderline for indicator 
PCBs (i-PCBs); indicator PCBs (also known 
as marker PCBs) include PCBs 28, 52, 101, 
118, 138, 153 and 180.
We next compared different adipose tissue 
territories. In a subset of obese subjects for 
which paired samples were available (n = 7), 
we found a strong correlation between the 
measured contamination levels in visceral 
(omental tissue) and subcutaneous depots 
before surgery for PCDD/PCDFs (Rs = 0.98, 
p < 0.0001), dl-PCBs (Rs = 0.99, p < 0.0001), 
or i-PCBs (Rs = 0.99, p < 0.0001). We there-
fore concluded that the easily accessible sub-
cutaneous depot pollutant concentrations 
represent a reliable estimate of adipose tissue 
contamination by pollutants.
To obtain a more global and realistic esti-
mation of POP contamination, and because 
POP concentration did not seem to be influ-
enced by the adipose tissue territory, we cal-
culated the total body burden of pollutants 
in each individual by multiplying the con-
centration values (expressed on a lipid weight 
basis) by the total fat mass estimated by 
DXA (“total POP burden”). The total POP 
burden in adipose tissue was increased by 
2.7-, 2.9-, and 2.8-fold in obese versus lean 
patients for PCDD/PCDFs (p < 0.0001), 
dl-PCBs (p < 0.001), and i-PCBs (p < 0.001) 
(Figure 1D). In obese subjects for which the 
two type of samples were available (n = 32), 
we observed a significant and strong corre-
lation before surgery between the contami-
nation levels in adipose tissue and blood for 
PCDD/PCDFs (Rs = 0.87, p < 0.0001), 
i-PCBs (Rs = 0.96, p < 0.0001), or dl-PCBs 
(Rs = 0.92, p < 0.0001). In lean subjects 
Table 2. Clinical and biological characteristics of subjects before and 3, 6, and 12 months after surgery.
After bypass
Clinical and biological parameters Before bypass 3 months 6 months 12 months p-Valuea
Adiposity markers
Body weight (kg) 130 ± 2.98 110.06 ± 2.60 99.93 ± 2.32 93.01 ± 2.48 < 0.0001
Resting energy expenditure (Kcal/24 hr) 1955.3 ± 49.8 NA 1604.7 ± 34.52 1582.4 ± 42.12 < 0.0001
BMI (kg/m2) 47.77 ± 0.79 40.28 ± 0.73 37.61 ± 0.70 34.03 ± 0.72 < 0.0001
Adipocyte diameter (μm) 115.46 ± 2.14 110.14 ± 2.24 105.53 ± 1.20 97.88 ± 1.73 < 0.0001
Fat mass (kg) 58.21 ± 1.46 48.26 ± 1.42 41.01 ± 1.31 33.31 ± 1.48 < 0.0001
Fat-free mass (kg) 62.84 ± 1.46 57.83 ± 1.46 55.57 ± 1.37 55.57 ± 1.61 < 0.0001
Leptin (ng/mL) 54.95 ± 3.27 26.69 ± 1.59 21.09 ± 1.54 17.61 ± 1.82 < 0.0001
Plasma glucose homeostasis and insulin sensitivity parameters
Glycemia (mmol/L) 6.07 ± 0.26 4.97 ± 1.11 4.79 ± 0.10 4.73 ± 0.15 < 0.0001
Insulinemia (μU/mL) 18.27 ± 1.43 9.00 ± 1.64 6.71 ± 0.56 6.33 ± 0.59 < 0.0001
HOMA-B 129.70 ± 6.71 108.86 ± 5.65 92.02 ± 5.34 102.94 ± 12.24 < 0.01
HOMA-S 61.28 ± 4.67 116.33 ± 8.19 175.21 ± 15.84 194.23 ± 22.91 < 0.0001
Adiponectin (μg/mL) 8.26 ± 0.93 8.11 ± 0.59 8.52 ± 0.54 11.03 ± 0.87 < 0.001
Plasma lipid homeostasis
Total cholesterol (mmol/L) 4.76 ± 0.12 4.34 ± 0.09 4.21 ± 0.12 4.37 ± 0.13 < 0.01
Total triglycerides (mmol/L) 1.36 ± 0.08 1.19 ± 0.05 1.12 ± 0.06 0.94 ± 0.007 < 0.0001
HDL cholesterol (mmol/L) 1.26 ± 0.04 1.17 ± 0.03 1.29 ± 0.04 1.74 ± 0.28 < 0.01
Liver tests
AST 27.97 ± 1.61 29.84 ± 1.31 25.90 ± 1.14 26.98 ± 1.67 < 0.05
ALT 38.65 ± 4.48 36.30 ± 3.01 28.86 ± 2.69 28.83 ± 2.65 < 0.05
γGT 52.97 ± 8.97 30.61 ± 4.41 26.39 ± 3.32 30.76 ± 5.16 < 0.001
Inflammatory markers
Plasma hsCRP (mg/L) 10.48 ± 1.12 5.64 ± 0.74 4.29 ± 0.62 2.71 ± 0.61 < 0.0001
Plasma IL6 (pg/mL) 9.12 ± 2.26 4.05 ± 0.56 3.41 ± 0.48 2.01 ± 0.22 0.0852
aTime-dependent changes were evaluated by multivariate analysis of variance.Kim et al.
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(n = 13), we found weaker correlations with 
Rs equal to 0.61 (p < 0.05), 0.80 (p < 0.001), 
and 0.35 (p < 0.05), respectively, for 
PCDD/PCDFs, i-PCBs, and dl-PCBs [see 
Supplemental Material, Figure 2 (doi:10.1289/
ehp.1002848)]. We observed strong posi-
tive correlations between subjects’ age and 
POP contamination levels measured in either 
adipose tissue (see Supplemental Material, 
Figure 3) or blood. Again, these correlations 
with age were stronger in obese than in lean 
subjects (Rs = 0.73 vs. 0.31, 0.68 vs. 0.41, and 
0.52 vs. 0.52 for PCDD/PCDFs, dl-PCBs, 
and i-PCBs, respectively).
Expression of pollutant target genes. We 
examined by reverse-transcriptase quantita-
tive polymerase chain reaction (RTqPCR) 
the expression of a series of adipose tissue 
genes known to be induced by these pollut-
ants as well as that of other relevant genes in 
subgroups of control and obese individuals, 
including only females. Several typical targets 
of the AhR, such as CYP1A1 (cytochrome 
P450 1A1), CYP19A1, and NQO1 [NAD(P)
H,quinone oxidoreductase-1], were up-regu-
lated in the adipose tissue of obese individu-
als (Figure 2). Interestingly, the expression 
of genes involved in low-grade inflamma-
tion associated with obesity such as COX-2 
(cyclooxygenase 2), CTSS (cathepsin S), and 
MMP9 (matrix metalloproteinase-9), which 
are also AhR target genes, was elevated in 
obese patients. These observations suggest that 
obesity is accompanied by an increased expres-
sion of POP-target genes. However, other 
obesity-related factors may account for these 
observations. We also monitored gene expres-
sion in blood cells, but this gave less conclusive 
data. Among POP target genes, only CYP1A1 
and IL1b (interleukin-1β) gene expression 
was significantly increased, independent of sex 
or age [see Supplemental Material, Figure 4 
(doi:10.1289/ehp.1002848)].
Association of POP levels with metabolic 
and liver parameters. PCDD/PCDF con-
centrations in adipose tissue (expressed per 
gram of lipids) correlated negatively both with 
body weight (pRs = –0.31, p < 0.05) and BMI 
(pRs = –0.25, p < 0.05), independent of age. 
We also found similar associations with other 
PCBs [see Supplemental Material, Table 1 
(doi:10.1289/ehp.1002848)].
We also observed significant positive asso-
ciations between POP contamination levels in 
blood (picograms or nanograms per liter) and a 
series of liver and metabolic parameters, mean-
ing that the higher the POP concentration in 
blood, the more deteriorated the liver function 
in these obese subjects. For example, serum 
i-PCBs correlated with AST (pRs = 0.64, 
p < 0.0001), ALT (pRs = 0.40, p < 0.05), and 
γGT (pRs = 0.58, p < 0.001). We also observed 
positive correlations with blood lipids as serum 
level of triglycerides (pRs= 0.36, p < 0.0001 
for i-PCBs) and total cholesterol (pRs = 0.38, 
p < 0.05 for i-PCBs). Data for other pollutants 
are shown in Supplemental Material, Table 1 
(doi:10.1289/ehp.1002848). 
POP levels and gene expression during 
weight loss. We examined changes in pollut-
ant abundance both in serum and adipose 
tissue during surgery-induced weight loss.   
Figure 2. Expression of pollutant target genes in adipose tissue of lean and obese subjects. High-quality 
RNA was available for seven lean and nine obese subjects. The relative expression was obtained by 
RTqPCR using the comparative Ct method by reporting Ct of target gene of each subject to mean Ct of 
lean subjects and by using RPL13A (60S ribosomal protein L13a) as reference gene. (A) AhR, phase I xeno-
biotic metabolizing CYP genes and other targets of the xenobiotic receptors. (B) Targets of the xenobiotic 
receptors involved in obesity-associated low-grade inflammation. For each gene, data for obese and lean 
subjects were statistically compared by Wilcoxon rank sum test. 
*p < 0.05. 
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Figure 1. Serum and adipose tissue POPs in lean and obese subjects. POPs were measured in serum of 35 
obese patients before surgery and in 17 lean subjects. (A,B) Measured POPs expressed on a lipid weight 
(l.w.) basis (A) or expressed on fresh weight basis (B) did not differ. Wilcoxon rank sum test was used for 
comparison. (C) Concentrations of POPs measured in adipose tissue of 18 lean versus 65 obese patients 
(before surgery). (D) Total body burdens (total charge) of POPs measured in adipose tissue of 12 lean 
versus 65 obese patients (before surgery), relative to the total fat mass. Twelve lean subjects and all obese 
subjects agreed to the DXA scan. Wilcoxon rank sum test was used for comparison. 
**p < 0.01. #p < 0.001.
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Surgery-induced weight loss was associ-
ated with a gradual and significant increase 
in the serum concentrations of POPs meas-
ured in obese patients whether expressed on 
a lipid weight basis or per milliliter of serum 
(Figure 3). At 12 months, the mean serum 
concentrations of pollutants were increased 
by 38%, 46%, and 48% compared with 
basal levels for PCDD/PCDFs, dl-PCBs, and 
i-PCBs respectively (Figure 3). The effect of 
this drastic perturbation on pollutant distri-
bution was similar for all congeners.
We observed a gradual increase in the 
concentrations of POPs (i.e., picograms or 
nanograms per gram lipid weight) in subcu-
taneous adipose tissue of obese subjects after 
weight loss (Figure 4A). In contrast, the total 
body burden of POPs, as calculated from adi-
pose tissue concentration and total fat mass, 
decreased continuously for dl-PCBs (p < 0.05) 
and for i-PCBs (p < 0.05) (Figure 4B). The 
decrease was approximately 10–15% at 6 
and 12 months postsurgery. After an initial 
decrease at 3 and 6 months, PCDD/F total 
body burden increased slightly but signifi-
cantly at 12 months after versus before sur-
gery (p < 0.01) (Figure 4B).
We evaluated gene expression in adipose 
tissue of obese subjects before and 6 months 
after surgery. Although some AhR target 
genes such as NQO1, SOS1 (son of seven-
less homolog 1), and AQP3 (aquaporin 3) 
decreased 6 months after surgery, CYP1B1 
and CYP1A1 did not vary significantly. Other 
xenobiotic metabolizing enzyme genes such 
as CYP2B6, CYP2U1 were significantly 
decreased after 6 months of weight loss. 
The decrease in inflammatory genes such as 
COX-2 and MMP9 also known to be POP 
target genes indicates that the expression 
of several POP target genes in adipose tis-
sue decreased after weight loss, whereas that 
of other targets was either unchanged or 
slightly increased [see Supplemental Material, 
Figure 5A (doi:10.1289/ehp.1002848)].
We also monitored gene expression in 
blood at 0, 1, 3, 6, and 12 months. Although 
the expression of several inflammatory genes 
decreased significantly over time, the expression 
of direct AhR target genes did not vary signifi-
cantly, although we observed a clear tendency 
for a decrease in the expression of the CYP1A1 
and CYP1B1 genes [see Supplemental Material, 
Figure 5B (doi:10.1289/ehp.1002848)].
Dynamic association studies during weight 
loss. Variations of all POP contamination 
levels after RYGB, in blood and adipose tis-
sue, displayed strong negative associations 
with a series of corpulence-related parameters 
[Figure 5; see also Supplemental Material, 
Table 2 (doi:10.1289/ehp.1002848)], includ-
ing BMI, body fat mass, leptin levels, and 
adipocyte volume. Interestingly, some of 
these associations remained significant even 
after adjustment for body fat mass variations 
(see Supplemental Material, Tables 2,3). 
For example, PCDD/PCDF blood lev-
els showed negative correlations with BMI 
(pRs = –0.44, p < 0.00001), adipocyte diam-
eter (pRs = –0.27, p < 0.01), and leptin serum 
levels (pRs = –0.29, p < 0.05) and a positive 
correlation with adiponectin serum levels 
(pRs = 0.30, p < 0.01). Some of these rela-
tionships remained significant after adjust-
ing for body fat mass variations, including 
those with adipocyte diameter (pRs = –0.13, 
p < 0.01) and adiponectin serum levels 
(pRs = 0.23, p < 0.01). We also found a nega-
tive correlation between resting metabolic rate 
and change in blood pollutants (for PCDD/
PCDFs, pRs = –0.27, p < 0.01). The associa-
tion depended on the changes of body com-
position–related parameters, such as total lean 
and fat mass or BMI, because the association 
disappeared after adjustment on these factors 
(data not shown).
Variations in POP contamination levels 
after surgery also displayed strong positive asso-
ciations with metabolic and hepatic parameters 
[see Supplemental Material, Table 2, Figure 5 
(doi:10.1289/ehp.  1002848)]. Importantly, 
most of these associations were independent 
of the variations in body fat mass after sur-
gery, thus indicating that the increase in POP 
concentrations after surgery associates with a 
delayed normalization of lipid- and liver-related 
parameters. For example, PCDD/PCDF blood 
concentrations correlated positively with serum 
levels of tri  glycerides (pRs = 0.20, p < 0.01), 
total cholesterol (pRs = 0.40, p < 0.00001), 
and γGT (pRs = 0.14, p < 0.01), independent 
of body fat mass variations. Surprisingly, we 
Figure 4. Adipose tissue POP concentrations before and after bariatric surgery in obese subjects. (A) Time 
course of the concentrations of POPs measured in adipose tissue of obese patients before and after sur-
gery expressed on a lipid weight (l.w.) basis. Measures were obtained in 37 obese subjects. At 12 months 
(M12), there was an increased concentration of 54%, 45%, and 64%, respectively, for PCDD/Fs, dl-PCBs, 
and i-PCBs versus before surgery (M0). (B) Time course of the amounts (total charge) of total body 
burdens of POPs measured in adipose tissue of obese patients before and after surgery (expressed in 
picograms and deduced for each POP family from the concentration reported in A and the total fat mass). 
Measures were obtained in 37 obese subjects. 
*p < 0.05, **p < 0.01, #p < 0.001 (Wilcoxon rank sum test comparing M3, M6, and M12 vs. M0).
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observed a positive association between concen-
trations of various POPs in adipose tissue and 
in blood and the improvement of HOMA-S 
(indicator of insulin sensitivity) and HOMA-B 
(indicator of pancreatic insulin secretion) after 
surgery even after adjustment for body fat mass 
variations.
Discussion
In the present study, we carried out a novel 
and comprehensive assessment in humans of 
the distribution and putative effects of sev-
eral POPs that are known to be preferentially 
localized into adipose tissue. We conducted 
the study in obese individuals undergoing 
drastic weight loss, a unique condition leading 
to the redistribution of endogenous POPs. We 
first showed that the patterns of POP conge-
ners distributions in the subcutaneous and 
visceral adipose tissue depots are extremely 
similar. This has already been shown for some 
organochlorine pollutants in postmortem 
studies by Dewailly et al. (1999). This obser-
vation has important practical implications 
because it suggests that the easily accessible 
subcutaneous adipose tissue is representative 
of the pollutants distribution in deeper fat 
depots and allowed us to estimate total POP 
body burden.
An important observation of this study 
was that the POP body burden is significantly 
higher in obese than in lean individuals, con-
firming and extending some previous studies 
(Wolff et al. 2005). However, the concen-
trations of adipose tissue POPs (per gram of 
lipid) in obese individuals were either smaller 
or similar to those of lean subjects, indicating 
that POPs are more dilute in obese fat mass 
and that the increased body burden is due 
to the larger fat mass compartment. We also 
observed increased POP target gene expres-
sion in the adipose tissue of obese individuals, 
but the interpretation of such an increase is 
unclear at this stage.
The study also highlights the impor-
tance of the size of the triglyceride droplet 
(i.e., mostly conditioning the adipocyte size) 
in controlling the release of POPs into the 
bloodstream, because diminished adipocyte 
size and weight loss have an impact on POP 
serum level. These data suggest that increased 
lipolysis associated with weight loss may lead 
to a faster exchange of POPs between the dif-
ferent body compartments. Nevertheless, we 
show that drastic weight loss leads to a sig-
nificant 10–15% decrease of the body burden 
of the most abundant POPs (i.e., dl-PCBs 
and i-PCBs) but not for PCDD/PCDFs. 
Although there is no clear explanation for the 
latter observation, POP body burden tends 
naturally to increase, at a rate of approximately 
3–5% per year [see Supplemental Material, 
Figure 3 (doi:10.1289/ehp.1002848)]. In 
addition, it is unclear whether the decrease 
in PCB body burden is due to elimination, as 
we suspect, or to a redistribution in a different 
nonfat compartment.
We addressed the impact of POP redistri-
bution on metabolism by exploring basal and 
dynamic correlations between POP release 
and the subjects’ metabolic changes. In agree-
ment with previous studies on organochlorine 
chemicals (reviewed by Pelletier et al. 2003), 
we observed a significant negative association 
between serum POPs and resting metabolic 
rate that is known to diminish after weight 
loss. However, this association did not remain 
when we adjusted comparisons for corpulence-
related parameters. This result indicates that 
POP release from adipose tissue and variations 
in body corpulence are not independent fac-
tors for the control of resting metabolic rates, 
suggesting that increased serum POPs may at 
least partially account for the decreased energy 
expenditure elicited by weight loss. Data from 
the literature suggest that such effects could 
be mediated by alteration in thyroid hor-
mone effects or metabolism (Pelletier et al. 
2003). We also observed a positive relation-
ship between plasma POPs and lipid (i.e., 
triglycerides and cholesterol) and liver (i.e., 
transaminases and γGT) parameters. In addi-
tion, although it is widely accepted that weight 
loss associates with metabolic and liver func-
tion improvements (Mathurin et al. 2009), we 
here observed a positive association between a 
diminished improvement of lipid values and 
of liver markers and increased POP plasma 
concentrations. Thus, although the beneficial 
effects of weight loss are always observed, they 
appear to be slowed down or decreased by 
higher POP levels. Obesity is a well-known 
important risk factor for nonalcoholic fatty 
liver disease, cirrhosis, and cancer (Siegel and 
Zhu 2009). The pathologic transformations 
of the adipose tissue in obese subjects, par-
ticularly increased cytokine and free fatty acid 
release, contribute to nonalcoholic fatty liver 
disease physiopathology (Brunt 2010; Tiniakos 
et al. 2010). Thus, our study raises the issue of 
a possible contribution to liver dysfunction of 
chronic internal exposure of obese subjects to 
POPs, in addition to other factors.
The assumption that POPs may jeopar-
dize all aspects of obese individual health is 
not straightforward. This is illustrated in our 
study, showing a positive correlation between 
the increase of plasma POPs and the improve-
ment of insulin sensitivity even after adjust-
ment for body fat mass. Although at first view 
these findings appear surprising based on pre-
vious observations suggesting an association 
Figure 5. Associations among variations of POPs serum and adipose tissue levels and bioclinical parameters: 
correlation circles computed through PCA illustrating significant associations among variations of POP levels 
in serum (A and B) or adipose tissue (C and D) (indicated here for PCDD/PCDFs) before (A,C) and after (B,D) 
adjusting for variations in total body fat mass after RYGB in an LME model. Positive associations with PCDD/
PCDF are indicated in blue, and negative ones in gray (FFM, fat-free mass; FM, fat mass). Similar results were 
obtained for the other two congeners [Supplemental Material, Tables 2, 3 (doi:10.1289/ehp.1002848)]. 
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between POPs and the incidence of diabetes 
(Fierens et al. 2003; Lee et al. 2008), they are 
in agreement with a previous exploration in 
less obese men showing that the increase of 
organochlorine pollutants in human serum 
was positively associated with the decrease in 
insulin levels after diet-induced weight loss 
(Imbeault et al. 2002). One possible mecha-
nistic explanation for these paradoxical effects 
can be deduced from studies showing that 
POPs such as dioxin lead to a decrease in liver 
gluconeogenesis in several cellular and ani-
mal models mainly through the repression of 
phosphenolpyruvate carboxykinase (Viluksela 
et al. 1999). Thus decreased liver glucose pro-
duction may compensate other deleterious 
metabolic effects of pollutants and lead to 
improved insulin-sensitivity biomarkers.
In conclusion, the comparison of obese 
and lean individuals, as well as the follow-up 
of obese subjects during weight loss, indicates 
that, in humans, POPs could be involved in 
the alteration of energy and lipid homeostasis 
and in liver dysfunction.
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